Department of Pathophysiology, Poznan University of Medical Sciences, Rokietnicka 8, 60-806 Poznań, Poland.
1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland.
Immun Ageing. 2014 Dec 4;11(1):23. doi: 10.1186/s12979-014-0023-7. eCollection 2014.
Interleukin-6 (IL-6) is an inflammatory cytokine whose levels increase significantly during myocardial infarction (MI). It has been hypothesised that the concentrations of IL-6 at admission may be useful in prognosticating long-term outcomes. It is unclear, however, whether IL-6 could improve the prognosis of early mortality in MI. We have compared serum IL-6 levels and analysed the disease course in 158 patients with ST-elevation MI (STEMI) who either survived (n = 148) or died (n = 10) within 30 days following the admission. Patients were treated in a single university centre with primary percutaneous coronary intervention (PCI). The non-survivors (6.3%) displayed most of typical risk factors for poor outcome. In addition they had significantly higher concentrations of IL-6 at hospital admission (median values 8.5 vs. 2.0 pg/ml; p = 0.038). However, they were also significantly older than the survivors (median values 72 vs. 57 years; p = 0.0001). IL-6 levels are known to increase with age and we could confirm a significant correlation between patients' calendar age and circulating IL-6 (p = 0.009). Regression analysis revealed that IL-6 concentrations were significantly affected by patients' age but they did not independently relate to patients' outcome. Such results indicate that circulating IL-6 at admission may be of limited value in predicting early mortality in STEMI. It is important to recognize that, because of the small group of patients who died (N = 10), the results must be interpreted with caution. Therefore, we stress that these results should be viewed as preliminary and further validated in a larger set of patients.
白细胞介素 6（IL-6）是一种炎症细胞因子，在心肌梗死（MI）期间其水平显著升高。有人假设入院时的 IL-6 浓度可能有助于预测长期预后。然而，尚不清楚 IL-6 是否可以改善 MI 早期死亡率的预后。我们比较了 158 例 ST 段抬高型心肌梗死（STEMI）患者的血清 IL-6 水平，并分析了他们的疾病进程，这些患者在入院后 30 天内存活（n=148）或死亡（n=10）。患者在单一大学中心接受经皮冠状动脉介入治疗（PCI）治疗。非幸存者（6.3%）表现出大多数不良预后的典型危险因素。此外，他们在入院时的 IL-6 浓度明显更高（中位数 8.5 vs. 2.0 pg/ml；p=0.038）。然而，他们也比幸存者明显更年长（中位数 72 岁 vs. 57 岁；p=0.0001）。已知 IL-6 水平随年龄增加而增加，我们可以确认患者的日历年龄与循环 IL-6 之间存在显著相关性（p=0.009）。回归分析显示，IL-6 浓度受患者年龄的显著影响，但与患者的预后无独立关系。这些结果表明，入院时的循环 IL-6 在预测 STEMI 早期死亡率方面可能价值有限。重要的是要认识到，由于死亡患者（N=10）人数较少，因此必须谨慎解释结果。因此，我们强调这些结果应被视为初步结果，并在更大的患者群体中进一步验证。
